TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06195072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: IP will be administered subcutaneously by the Investigator or designee as follows:~* Amlitelimab or~* Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Study participants will take the active investigational product BI 1015550 or matching placebo provided as film-coated tablets, administered orally BID.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: see Experimental Arm intervention description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: see Experimental Arm intervention description
Study: NCT06234124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Variable Friction Shoe Training
Description: The experimental group (A) will be given a pair of VF shoes and instructed to use shoes on both feet. This group will be instructed to walk on hard surfaces to engage auditory feedback of the VF shoes. This group group will be monitored daily using actigraphy and will receive weekly check-up telephone calls by a member of the research team to record number of steps, walking time, a scale for self-identified effort and perceived safety levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Variable Friction Shoe Training
Description: The experimental group (A) will be given a pair of VF shoes and instructed to use shoes on both feet. This group will be instructed to walk on hard surfaces to engage auditory feedback of the VF shoes. This group group will be monitored daily using actigraphy and will receive weekly check-up telephone calls by a member of the research team to record number of steps, walking time, a scale for self-identified effort and perceived safety levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Foot Orthosis (AFO) Training
Description: The control group (B) will be provided an AFO to use on the paretic limb. This group will be instructed to walk on hard surfaces. This group group will be monitored daily using actigraphy and will receive weekly check-up telephone calls by a member of the research team to record number of steps, walking time, a scale for self-identified effort and perceived safety levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Foot Orthosis (AFO) Training
Description: The control group (B) will be provided an AFO to use on the paretic limb. This group will be instructed to walk on hard surfaces. This group group will be monitored daily using actigraphy and will receive weekly check-up telephone calls by a member of the research team to record number of steps, walking time, a scale for self-identified effort and perceived safety levels.
Study: NCT05368714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Economic Empowerment (EE)
Description: EE will be provided via a child development account (CDA). CDAs provide children with basic financial education, introduce them to formal financial institutions, and incentivize them to save by matching their deposits. Any of the child's family members, relatives, or friends will be allowed and encouraged to contribute towards the CDA. The account will be matched with money from the program. The maximum family contribution to be matched by the program will be an equivalent of US $10 per month per family or US $120 for the 12-month intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Family Group based Family Strengthening (MFG-based FS)
Description: MFG-based FS approach is a family-centered, group delivered, evidence-informed, strength-based intervention designed for children and adolescents whose families struggle with poverty and associated stressors. MFG is based on building support for parents and families by providing opportunities for parents and children to communicate in a safe setting with other families who have shared experiences. The core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support. Participants in this study arm will receive 16 session of MFG-based FS sessions, delivered by delivered by trained Community Health Workers and Parent Peers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EE plus MFG-based FS
Description: EE plus MFG-based FS directly addresses both the economic needs and mental health functioning. It will consists of an EE intervention that comprises a family monetary savings program using CDAs, and a family-based dialogue and training via MFG focused on strengthening family relationships and mental health challenges.
Study: NCT06320080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2223 injection
Description: TQB2223 is an anti- lymphocyte activation gene-3 (LAG-3) antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab Injection
Description: Penpulimab Injection is an anti programmed death-1 (PD-1) antibody.
Study: NCT05564052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered either intravenously or subcutaneously.
Study: NCT05838300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warm humidified CO2
Description: Participants will receive warm (37°C) and humidified (95%) CO2.The humidification and warming device to be used is AlwaysPneumo® AP 50/30 InsuflowPort® (Lexion Medical, FDA approved) which is a specialized port that delivers warmed (95° F) and humidified (95% relative humidity) CO2, the source of which is a standard CO2 tank or wall source

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry CO2
Description: Participants will receive standard cold (19-21 °C) and non-humidified (0%) CO2 insufflation with Airseal Insufflator
Study: NCT05798520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DRF
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRF
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRF
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DRF
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT04993352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection
Description: 0.05mL (12.5mg/0.5mL/vial) HLX-04-O solution at a 4-week interval for intravitreal injection
Study: NCT06133621

Intervention type: OTHER
Intervention: dosage dRVVT
Description: Blood test dRVVT assay on two tubes of blood in the haemostasis laboratory of the Center de Biologie et de Pathologie Est

Intervention type: OTHER
Intervention: dosage dRVVT
Description: Blood test dRVVT assay on two tubes of blood in the haemostasis laboratory of the Center de Biologie et de Pathologie Est
Study: NCT05479175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diode laser
Description: Diode laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nonactive Diode laser
Description: Nonactive Diode laser
Study: NCT04725175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPE-307
Description: Single and multiple ascending oral doses of PIPE-307 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Single and multiple ascending oral doses of matching Placebo tablets
Study: NCT05798520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT06645106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid Point of Care (POC) Syphilis testing
Description: Participants will undergo the point of care (POC) FDA cleared syphilis health check (SHC) POC test by a research staff using 50 microliters or 1-3 drops of whole blood via finger stick. The analyzer is handheld, and all testing equipment is temperature stable and does not need refrigeration. The SHC-Syphilis results will be available within 10 minutes of receipt given the published turnaround time to results of 15 minutes per package insert and will be recorded as a research note in the electronic medical record (EMR) while the provider assigned to the patient and the Houston Health Department will be notified of results and further treatment will be done if results are positive.
Study: NCT05874479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active PAC
Description: The active PAC will contain HEPA filters inside the device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PAC
Description: The sham PAC will contain no HEPA filters inside the device.
Study: NCT06455774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Postural Feedback Device
Description: The postural feedback wearable device we will use in the study is programmed to vibrate when hunched postures are detected (based on changes in the curvature and curvature of the spine), alerting users to changes in their body position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Trapezius, Sternocleidomastoid (SCM), Scalene, pectoral muscles will be targeted for stretching exercises and deep neck flexors, Trapezius, Levator Scapula, Rhomboids will be targeted for strengthening exercises. The intensity of the exercises will be increased according to the weeks. Stretching exercises will be performed as a single set at the pain limit, maintaining the position of the muscle groups in the longest tolerable position for 30 seconds. In strengthening exercises, participants will hold the position for 5-10 seconds at the end of the movement. Moderate resistance elastic bands and free weights will be used for resistance exercises. In the following weeks, progression will be made in all exercises according to the patient's condition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Trapezius, Sternocleidomastoid (SCM), Scalene, pectoral muscles will be targeted for stretching exercises and deep neck flexors, Trapezius, Levator Scapula, Rhomboids will be targeted for strengthening exercises. The intensity of the exercises will be increased according to the weeks. Stretching exercises will be performed as a single set at the pain limit, maintaining the position of the muscle groups in the longest tolerable position for 30 seconds. In strengthening exercises, participants will hold the position for 5-10 seconds at the end of the movement. Moderate resistance elastic bands and free weights will be used for resistance exercises. In the following weeks, progression will be made in all exercises according to the patient's condition.
Study: NCT05839119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: initial dose is 240 mg administered as two 120 mg (3 mL) injections (SC), followed by subsequent doses at 80 mg (4 mL) administered as one injection (SC)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin
Description: SOC Neoadjuvant Chemotherapy: Gemcitabine/Cisplatin 21-day cycles (4 cycles total)~* Gemcitabine: 1000 mg/m2 (IV) Days 1 and 8 of each cycle~* Cisplatin: 70 mg/m2 (if borderline renal function: 35 mg/m2) (IV) Day 1 of each cycle (if borderline renal function, days 1 and 8 of each cycle).
Study: NCT06315569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Run 3000 meters
Description: Participants in both groups were asked to do two 3,000-meter runs at different intervals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Run 3000 meters
Description: Participants in both groups were asked to do two 3,000-meter runs at different intervals
Study: NCT06635577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verbal Interference Task
Description: During the second half of the study, participants will undergo an interference task such as repetition of the word the; or shadowing a radio broadcast in order to increase cognitive load and disrupt the use of a mental workspace.
Study: NCT05036447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate-Heavy Resistance Exercise
Description: Leg press: 3 x 8 repetitions at 75% of 1 repetition maximum, 3 minutes rest between sets.~Knee extension: 3 x 6 repetitions at 85% of 1 repetition maximum, 3 minutes rest between sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate-Heavy Resistance Exercise
Description: Leg press: 3 x 8 repetitions at 75% of 1 repetition maximum, 3 minutes rest between sets.~Knee extension: 3 x 6 repetitions at 85% of 1 repetition maximum, 3 minutes rest between sets.
Study: NCT06638619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback Fixation Training
Description: This training type involves the use of microperimetry. Microperimetry is a visual field test that incorporates perimetry and retinal imaging and is a standard ophthalmic clinical technology. It allows for direct observation of the fundus, but uses an eye-tracking system to compensate for involuntary eye movements. A program designed to train patients to direct and hold their gaze at an eccentric location programmed by the controller will be used. When the participant directs their gaze towards the pre-programmed location, a sound of increasing frequency is emitted to let them know they are approaching the correct location. The sound stabilizes into a solid tone when the patient is gazing directly at the trained location (biofeedback) and they are asked to attempt to hold their gaze at this location for as long as possible.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Saccadic Reading Training
Description: Participants will be assigned to participate in an at-home reading program. The reading exercises consist of worksheets with letter and number combinations of increasing complexity and font sizes. They are intended to increase accuracy in identifying letters and numbers. Worksheets will initially be dispensed with larger font type and spacing and be graded at weekly intervals towards regular, newspaper-size print and spacing over the course of training.
Study: NCT05664841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: magic trick training
Description: A typical session will begin with the magician demonstrating a magic trick then revealing the secret move of the trick.The participants will learn and practice each trick. With assistance from the magician, participants will develop an oralstory presentation for the trick. After participants master one trick, the magician will demonstrate and teach the next.
Study: NCT04853888

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ATTACH™ Parenting Program
Description: ATTACH™ parenting program offers an innovative, novel approach to early intervention, focusing on improving parent-child relationship quality by targeting parents' underlying reflective function (RF)-the ability to better understand one's own and one's child's thoughts and feelings. RF is essential for high quality parent-child relationships and secure parent-child attachment, both tied to child development and health, especially cognition, communication and inflammation.~.
Study: NCT06566183

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guideline-directed medical therapy (GDMT)
Description: Participants receive guideline-directed medical therapy (GDMT).
Study: NCT05560867

Intervention type: DEVICE
Group type: OTHER
Intervention: robot-assisted training
Description: These training platforms use gamified training tasks to improve motor control in the hemiparetic arm
Study: NCT05548075

Intervention type: DRUG
Intervention: Psilocybin
Description: Up to 25mg of Psilocybin on 2 occasions.

Intervention type: BEHAVIORAL
Intervention: Therapeutic support
Description: Psychological and physical therapeutic support
Study: NCT06419127

Intervention type: DIAGNOSTIC_TEST
Intervention: Timelapse incubation and PGT
Description: Patients will have their embryos cultured in a timelapse incubator and their PGT results will be compared to the data collected during timelapse incubation.
Study: NCT06068816

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrient-dense drink
Description: a nutrient-dense drink developed by FrieslandCampina in line with the European Society for Clinical Nutrition and Metabolism guidelines for the dietary management of older malnourished patients
Study: NCT05487131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electrical stimulation
Description: different types of weak electrical stimulation will be used

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electrical stimulation
Description: different types of weak electrical stimulation will be used
Study: NCT05965726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxlovid 25 day dosing
Description: nirmatrelvir 300mg and ritonavir 100mg taken bid for 30 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxlovid 15 day dosing
Description: nirmatrelvir 300mg and ritonavir 100mg taken bid for 15 days then ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid for 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid for 30 days
Study: NCT06574204

Intervention type: DRUG
Intervention: Erythromycin
Description: The researchers injected 30 units of erythromycin into the inner right wrist of the subjects, which is a liquid dosage form.

Intervention type: DRUG
Intervention: Azithromycin
Description: The researchers injected 30 units of azithromycin into the inner right wrist of the subjects, which is a liquid dosage form.

Intervention type: OTHER
Intervention: physiological saline
Description: The researchers injected 10-20 μl of physiological saline into the inner left wrist of the subjects, which is a liquid dosage form.
Study: NCT06573827

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine sample evaluation
Description: Blood and urine sample evaluation will be performed in healthy female volunteers.
Study: NCT06573268

Intervention type: DEVICE
Intervention: robot surgery device
Description: SPRA used da-Vinci SP system (SPRA) BABA used da-Vinci Xi system (BABA)

Intervention type: DEVICE
Intervention: robot surgery device
Description: SPRA used da-Vinci SP system (SPRA) BABA used da-Vinci Xi system (BABA)
Study: NCT06573125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MoodMover
Description: MoodMover is a 9-week app-based program aimed at increasing physical activity (PA) among individuals with depression, delivered via Pathverse. The current version of MoodMover includes one introductory module for baseline self-monitoring, eight primary modules, and eight optional supplementary modules. The program uses a variety of formats to deliver educational content, including videos, podcasts, and illustrated articles. In addition to its structured psychoeducational content, the app provides a range of behavioral features.
Study: NCT06497517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK5464714- Camlipixant
Description: GSK5464714- Camlipixant will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK5464714- Camlipixant
Description: GSK5464714- Camlipixant will be administered
Study: NCT06561113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine intake
Description: One cup of Turkish coffee contains 60 mg/65 ml (1 Turkish coffee cup) of caffeine. Participants will be instructed to sit for 10 minutes before drinking coffee. To prepare the Turkish coffee, 5 g of ground dry coffee will be mixed in 100 mL of tap water and left to boil in a coffee machine. When the first boil starts, it will be removed from the machine and poured into the cup. Then, 65 ml of Turkish coffee will be given to the subjects to ensure oral caffeine intake.
Study: NCT06573645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will be randomized to receive either rituximab 500 mg/m2 or rituximab 375 mg/m2 for six cycles of R-CHOP (21 days per cycle), followed by two maintenance cycles of rituximab (21 days per cycle).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Patients will be randomized to receive either rituximab 500 mg/m2 or rituximab 375 mg/m2 for six cycles of R-CHOP (21 days per cycle), followed by two maintenance cycles of rituximab (21 days per cycle).
Study: NCT06566183

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Description: Participants receive coronary artery bypass grafting (CABG).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI).
Description: Participants receive percutaneous coronary intervention (PCI).
Study: NCT06581848

Intervention type: DRUG
Intervention: Elranatamab
Description: According to the approved label, the recommended doses are step-up doses of 12 mg on day 1 and 32 mg on day 4, followed by a full treatment dose of 76 mg weekly from week 2 to week 24. For patients who have received at least 24 weeks of treatment and have achieved a response, the dosing interval should transition to an every two week schedule.
Study: NCT06116994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The buccal infiltration anesthesia with a camouflaged dental syringe (Angelus ™)
Description: In the test group, subjects will receive buccal infiltration anesthesia with the a camouflaged dental syringe. The used camouflaged dental syringe (Angelus ™) will consist of an alligator-shaped syringe sleeve that covers the dental syringe and makes it more friendly without affecting its function. The alligator-shaped syringe sleeve has three main components, which are the mouth, trunk, and rear feet. The mouth of the alligator sleeve covers the local anesthesia needle, the trunk covers the syringe barrel of the traditional dental syringe, and the rear feet hold the finger grip.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The buccal infiltration anesthesia with a conventional dental syringe
Description: In the control group, subjects will receive buccal infiltration anesthesia with the conventional dental syringe.